Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc., as indicated in the metadata) on March 26, 2008, reporting events occurring on March 20, 2008. The filing details the entry into material definitive agreements for the sale of unregistered equity securities to Korean investors.
Key Financial Metrics and Transaction Details
The filing reports two new Securities Purchase Agreements entered into on March 20, 2008, with closings scheduled for March 28, 2008:
- Jungwoo Family Co., Ltd.: Purchase of 285,715 shares of common stock and a warrant for 57,143 shares for total consideration of $400,001.00.
- Super Bio Co. Ltd.: Purchase of 357,143 shares of common stock and a warrant for 71,429 shares for total consideration of $500,000.20.
- Net Proceeds: The company expects to receive approximately $900,001.20 in net proceeds after expenses.
- Use of Proceeds: General corporate purposes.
- Warrant Terms: Exercise price of $1.80 per share; exercisable for three years.
The filing does not provide revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Prior Agreements
The March 20, 2008 agreements with Jungwoo Family Co., Ltd. replaced a prior agreement dated December 17, 2007. Under the December agreement, Jungwoo was obligated to purchase an additional 1,285,714 shares and a warrant for 257,143 shares for $1,799,999.60 at a closing scheduled for February 29, 2008. That closing did not occur. The new March 20 agreement releases Jungwoo from the obligation to purchase the remaining securities under the December agreement.
Outlook, Risks, and Contingencies
- Anti-Dilution Protection: Both agreements include "full ratchet" anti-dilution protection for two years. If the company issues stock below $1.40 per share, investors receive additional shares to adjust their effective purchase price. Warrants have similar protection if stock is issued below $1.80.
- Listing Obligation: The company is obligated to use commercially reasonable efforts to list its common stock on the American Stock Exchange (AMEX) within three years.
- Regulatory Status: The securities were sold in offshore transactions outside the United States under Regulation S and Section 4(2) of the Securities Act. They are unregistered and cannot be resold in the U.S. without registration or an exemption.
Investor Verification Checklist
- Verify the successful closing of the transactions on March 28, 2008, and the actual receipt of the ~$900,000 net proceeds.
- Confirm the company's progress toward listing on the AMEX within the three-year deadline.
- Monitor future equity issuances to assess the potential dilution impact of the "full ratchet" anti-dilution provisions.
- Review the company's financial statements (10-K or 10-Q) for actual revenue, cash flow, and debt levels, as this 8-K does not contain them.